{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:51:53Z","timestamp":1781639513411,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Inonu University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study examined the clinical, genetic, and treatment response characteristics of pediatric patients with acute myeloid leukemia (AML) treated according to the 2004 and 2012 AML-BFM protocols. This study aimed to determine survival outcomes and the factors affecting them, and to compare the results with international data. This study retrospectively evaluated pediatric AML patients aged\u2009&lt;\u200918 years in eastern Turkey between January 2010 and December 2023. The AML-BFM 2004 and AML-BFM 2012 protocols were applied to the patients. The risk groups of the patients were determined based on their responses to chemotherapy and genetic results. Survival analyses were conducted using the Kaplan\u2013Meier method. Univariate and multivariate Cox regression analyses were used. Forty-nine patients were included in this study. The median age at diagnosis was 12 years, and 51% of the patients were female. The most common morphological subtype was AML M3, accounting for 32.7% of cases. Complete remission was achieved in 81.6% of patients after induction therapy, whereas 12.2% died during this phase. Relapse occurred in 26.5% of patients. Overall, 38.8% of patients died. AML-M3 patients had a median overall survival (OS) of 113 months, which was better than that of non-AML-M3 patients. Five-year survival rates were 94% for AML-M3 patients and 43% for non-AML-M3 patients. Lower survival rates were observed in patients with leukocyte counts\u2009\u2265\u200950\u2009\u00d7\u200910\u2079\/L, low hemoglobin levels, non-AML-M3, and poor induction response. Mortality was higher in patients younger than two years and &gt;\u200914 years. There were no significant differences in mortality, survival, or relapse rates between the AML-BFM 2004 and AML-BFM 2012 protocols (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.005). No significant association was observed between mortality and leukapheresis. Further research should focus on developing personalized treatments for high-risk patients and those without non-AML-M3, given their poorer survival rates than those of AML-M3 patients.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-06906-4","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:43:14Z","timestamp":1772077394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Outcomes and Factors Affecting Survival in Pediatric Acute Myeloid Leukemia"],"prefix":"10.1007","volume":"105","author":[{"given":"Yurday","family":"\u00d6nc\u00fcl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Akyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beng\u00fc","family":"Macit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dcnsal","family":"\u00d6zgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"6906_CR1","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","volume":"32","author":"M Rasche","year":"2018","unstructured":"Rasche M, Zimmermann M, Borschel L et al (2018) Successes and challenges in the treatment of pediatric acute myeloid leukemia: A retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 32:2167\u20132177. https:\/\/doi.org\/10.1038\/s41375-018-0071-7","journal-title":"Leukemia"},{"issue":"18","key":"6906_CR2","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1200\/JCO.23.01841","volume":"42","author":"A Tierens","year":"2024","unstructured":"Tierens A, Arad-Cohen N, Cheuk D et al (2024) Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease. J Clin Oncol 42(18):2174\u20132185","journal-title":"J Clin Oncol"},{"issue":"18","key":"6906_CR3","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.3390\/cancers13184536","volume":"13","author":"M Czoga\u0142a","year":"2021","unstructured":"Czoga\u0142a M, Balwierz W, Pawi\u0144ska-W\u0105sikowska K et al (2021) Advances in the first line treatment of pediatric acute myeloid leukemia in the Polish pediatric leukemia and lymphoma study group from 1983 to 2019. Cancers (Basel) 13(18):4536.","journal-title":"Cancers (Basel)"},{"issue":"19","key":"6906_CR4","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1002\/cncr.30791","volume":"123","author":"TB Alexander","year":"2017","unstructured":"4.Alexander TB, Wang L, Inaba H et al (2017) Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. Cancer 123(19):3791\u20133798.","journal-title":"Cancer"},{"issue":"18","key":"6906_CR5","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1182\/blood-2013-01-476614","volume":"121","author":"5SL Aplenc","year":"2013","unstructured":"Aplenc 5SL, Alonzo R, Gerbing TA, Lehrnbecher RB, Gamis T AS (2013) Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the children\u2019s oncology group\u2019s oncology group. Blood 121(18):3573\u20133577","journal-title":"Blood"},{"issue":"4","key":"6906_CR6","doi-asserted-by":"publisher","first-page":"e28099","DOI":"10.1002\/pbc.28099","volume":"67","author":"K Klein","year":"2020","unstructured":"Klein K, van Litsenburg RRL, de Haas V et al (2020) Causes of early death and treatment-related death in newly diagnosed pediatric acute myeloid leukemia: recent experiences of the Dutch childhood oncology group. Pediatr Blood Cancer 67(4):e28099","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"6906_CR7","first-page":"166","volume":"26","author":"X Xin","year":"2021","unstructured":"Xin X, Zhu H, Chang Z et al (2021) Risk factors and prognosis analysis of acute myeloid leukemia in children. J BUON 26(1):166\u2013172","journal-title":"J BUON"},{"key":"6906_CR8","first-page":"1034","volume":"5","author":"A Plana","year":"2021","unstructured":"Plana A, Furner B, Palese M et al (2021) Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. JCO Clin Cancer Inf 5:1034\u20131043","journal-title":"JCO Clin Cancer Inf"},{"key":"6906_CR9","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","volume":"33","author":"CM Zwaan","year":"2015","unstructured":"Zwaan CM, Kolb EA, Reinhardt D et al (2015) Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol 33:2949\u20132962. https:\/\/doi.org\/10.1200\/JCO.2015.62.8289","journal-title":"J Clin Oncol"},{"issue":"9","key":"6906_CR10","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.21873\/anticanres.15951","volume":"42","author":"J Stankiewicz","year":"2022","unstructured":"Stankiewicz J, Styczynski J (2022) Improved Outcome in Pediatric Acute Myeloid Leukemia: Progress With Hematopoietic Cell Transplantation. Anticancer Res 42(9):4499\u20134504","journal-title":"Anticancer Res"},{"issue":"10","key":"6906_CR11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","volume":"129","author":"Y Abaza","year":"2017","unstructured":"11.Abaza Y, Kantarjian H, Garcia-Manero G (2017) al Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129(10):1275\u20131283. https:\/\/doi.org\/10.1182\/blood-2016-09-736686","journal-title":"Blood"},{"issue":"6","key":"6906_CR12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","volume":"20","author":"U Platzbecker","year":"2017","unstructured":"Platzbecker U, Avvisati G, Cicconi L et al (2017) Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol 20(6):605\u2013612","journal-title":"J Clin Oncol"},{"issue":"13","key":"6906_CR13","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","volume":"16","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK, UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group (2015) Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol 16(13):1295\u20131305. https:\/\/doi.org\/10.1016\/S1470-2045(15)00193-X","journal-title":"Lancet Oncol"},{"issue":"2","key":"6906_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jped.2020.02.003","volume":"97","author":"RV Morais","year":"2021","unstructured":"Morais RV, Souza MV, Silva KAS et al (2021) Epidemiological evaluation and survival of children with acute myeloid leukemia. J Pediatr (Rio J) 97(2):204\u2013210. https:\/\/doi.org\/10.1016\/j.jped.2020.02.003","journal-title":"J Pediatr (Rio J)"},{"key":"6906_CR15","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1182\/blood.v98.6.1714","volume":"98","author":"DK Webb","year":"2001","unstructured":"15.Webb DK, Harrison G, Stevens RF et al (2001) Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 98:1714\u20131720. https:\/\/doi.org\/10.1182\/blood.v98.6.1714","journal-title":"Blood"},{"issue":"11","key":"6906_CR16","doi-asserted-by":"publisher","first-page":"e31948","DOI":"10.1016\/j.heliyon.2024.e31948","volume":"10","author":"T Wu","year":"2024","unstructured":"16.Wu T, Fu W, Xue Y et al (2024) Health-related quality of life in children with childhood acute myeloid leukemia in China: A five-year prospective study. Heliyon 10(11):e31948. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31948","journal-title":"Heliyon"},{"key":"6906_CR17","doi-asserted-by":"publisher","first-page":"e26520","DOI":"10.1002\/pbc.26520","volume":"64","author":"HK St\u00f8ve","year":"2017","unstructured":"St\u00f8ve HK, Sandahl JD, Abrahamsson J et al (2017) Extramedullary leukemia in children with acute myeloid leukemia: a population-based cohort study from the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Pediatr Blood Cancer 64:e26520. https:\/\/doi.org\/10.1002\/pbc.26520","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"6906_CR18","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1038\/sj.leu.2403131","volume":"17","author":"BL Abbott","year":"2003","unstructured":"Abbott BL, Rubnitz JE, Tong X et al (2003) Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: A single institution\u2019s experience. Leukemia 17(11):2090\u20132096. https:\/\/doi.org\/10.1038\/sj.leu.2403131","journal-title":"Leukemia"},{"key":"6906_CR19","doi-asserted-by":"publisher","first-page":"104558","DOI":"10.1016\/j.critrevonc.2024.104558","volume":"205","author":"NR Moretti","year":"2025","unstructured":"Moretti NR, Silva ABND, Guimar\u00e3es LV et al (2025) The prevalence of solid tumors and hematologic malignancies among patients with Down syndrome: A systematic review and meta-analysis. Crit Rev Oncol Hematol 205:104558. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104558","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"6906_CR20","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2012-03-414755","volume":"120","author":"T Taga","year":"2012","unstructured":"Taga T, Saito AM, Kudo K et al (2012) Clinical characteristics and outcome of refractory\/relapsed myeloid leukemia in children with Down syndrome. Blood 120(9):1810\u20131815. https:\/\/doi.org\/10.1182\/blood-2012-03-414755","journal-title":"Blood"},{"issue":"9","key":"6906_CR21","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.3324\/haematol.2022.281106","volume":"1","author":"G Egan","year":"2023","unstructured":"Egan G, Tasian SK (2023) Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023. Haematologica 1(9):2275\u20132288. https:\/\/doi.org\/10.3324\/haematol.2022.281106","journal-title":"Haematologica"},{"issue":"3","key":"6906_CR22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s11845-020-02181-y","volume":"189","author":"GP Dowling","year":"2020","unstructured":"Dowling GP, Piccin A, Gavin KT et al (2020) A retrospective study of myeloid leukaemia in children with Down syndrome in Ireland. Ir J Med Sci 189(3):979\u2013984. https:\/\/doi.org\/10.1007\/s11845-020-02181-y","journal-title":"Ir J Med Sci"},{"issue":"2","key":"6906_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000117712","volume":"119","author":"E Mantadakis","year":"2008","unstructured":"Mantadakis E, Samonis G, Kalmanti MA (2008) comprehensive review of acute promyelocytic leukemia in children. Acta Haematol 119(2):73\u201382. https:\/\/doi.org\/10.1159\/000117712","journal-title":"Acta Haematol"},{"issue":"5","key":"6906_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1600-0609.2009.01308.x","volume":"83","author":"KN Manola","year":"2009","unstructured":"Manola KN (2009) Cytogenetics of pediatric acute myeloid leukemia. Eur J Haematol 83(5):391\u2013405. https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01308.x","journal-title":"Eur J Haematol"},{"key":"6906_CR25","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","volume":"111","author":"ZY Wang","year":"2008","unstructured":"Wang ZY, Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111:2505\u20132515. https:\/\/doi.org\/10.1182\/blood-2007-07-102798","journal-title":"Blood"},{"key":"6906_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa1300874","journal-title":"N Engl J Med"},{"issue":"6","key":"6906_CR27","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s12098-023-04689-4","volume":"91","author":"S Srinivasan","year":"2024","unstructured":"Srinivasan S, Dhamne C, Moulik NR et al (2024) Treatment of Pediatric Acute Promyelocytic Leukemia with Retinoic Acid and Arsenic Trioxide along with Chemotherapy. Indian J Pediatr 91(6):564\u2013570. https:\/\/doi.org\/10.1007\/s12098-023-04689-4","journal-title":"Indian J Pediatr"},{"issue":"1","key":"6906_CR28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1186\/s12885-024-12404-5","volume":"24","author":"W Mamo","year":"2024","unstructured":"Mamo W, Moges A, Yesuf SA, Mohamedsaid A, Arega G (2024) Treatment outcomes of pediatrics acute myeloid leukemia (AML) and associated factors in the country\u2019s tertiary referral hospital, Ethiopia. BMC Cancer 24(1):640. https:\/\/doi.org\/10.1186\/s12885-024-12404-5","journal-title":"BMC Cancer"},{"issue":"1","key":"6906_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamaoncol.2021.5206","volume":"8","author":"MA Kutny","year":"2022","unstructured":"Kutny MA, Alonzo TA, Abla O et al (2022) Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children\u2019s Oncology Group AAML1331 Trial. JAMA Oncol 8(1):79\u201387. https:\/\/doi.org\/10.1001\/jamaoncol.2021.5206","journal-title":"JAMA Oncol"},{"issue":"1324","key":"6906_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1182\/blood-2018-03-836528","volume":"26","author":"AM Testi","year":"2018","unstructured":"Testi AM, Pession A, Diverio D et al (2018) Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood 26(1324):405\u2013412. https:\/\/doi.org\/10.1182\/blood-2018-03-836528","journal-title":"Blood"},{"key":"6906_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3324\/haematol.2009.017962","volume":"95","author":"M Breccia","year":"2010","unstructured":"Breccia M, Latagliata R, Cannella L, Minotti C, Meloni G, Lo-Coco F (2010) Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: Association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica 95:853\u2013854. https:\/\/doi.org\/10.3324\/haematol.2009.017962","journal-title":"Haematologica"},{"issue":"1","key":"6906_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2141.2011.08922x","volume":"156","author":"KA Breen","year":"2012","unstructured":"Breen KA, Grimwade D, Hunt BJ (2012) The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia. Br J Haematol 156(1):24\u201336. https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08922x","journal-title":"Br J Haematol"},{"key":"6906_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.canep.2018.03.001","volume":"54","author":"S Xie","year":"2018","unstructured":"Xie S, Hossain MJ (2018) Survival differences in childhood and young adult acute myeloid leukemia: A cross-national study using US and England data. Cancer Epidemiol 54:19\u201324. https:\/\/doi.org\/10.1016\/j.canep.2018.03.001","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"6906_CR34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12288-015-0591-5","volume":"32","author":"V Radhakrishnan","year":"2016","unstructured":"Radhakrishnan V, Thampy C, Ganesan P et al (2016) Acute myeloid leukemia in children: experience from Tertiary Cancer Centre in India. Indian J Hematol Blood Transfus 32(3):257\u2013261. https:\/\/doi.org\/10.1007\/s12288-015-0591-5","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"1","key":"6906_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5045\/br.2018.53.1.25","volume":"53","author":"TY Song","year":"2018","unstructured":"Song TY, Lee SH, Kim G, Baek HJ, Hwang TJ, Kook H (2018) Improvement of treatment outcome over 2 decades in children with acute myeloid leukemia. Blood Res 53(1):25\u201334. https:\/\/doi.org\/10.5045\/br.2018.53.1.25","journal-title":"Blood Res"},{"key":"6906_CR36","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/ijc.23428","volume":"122","author":"R Swaminathan","year":"2008","unstructured":"Swaminathan R, Rama R, Shanta V (2008) Childhood cancers in Chennai, India, 1990\u20132001: Incidence and survival. Int J Cancer 122:2607\u20132611. https:\/\/doi.org\/10.1002\/ijc.23428","journal-title":"Int J Cancer"},{"issue":"3","key":"6906_CR37","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.htct.2018.09.007","volume":"41","author":"AL Nunes","year":"2019","unstructured":"Nunes AL, Paes CA, Murao M, Viana MB, De Oliveira BM (2019) Cytogenetic abnormalities, WHO classification, and evolution of children and adolescents with acute myeloid leukemia. Hematol Transfus Cell Ther 41(3):236\u2013243. https:\/\/doi.org\/10.1016\/j.htct.2018.09.007","journal-title":"Hematol Transfus Cell Ther"},{"issue":"12","key":"6906_CR38","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(22)00637-4","volume":"23","author":"L Botta","year":"2022","unstructured":"Botta L, Gatta G, Capocaccia R et al (2022) EUROCARE-6 Working Group. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study. Lancet Oncol 23(12):1525\u20131536. https:\/\/doi.org\/10.1016\/S1470-2045(22)00637-4","journal-title":"Lancet Oncol"},{"issue":"7","key":"6906_CR39","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/ijc.33878","volume":"150","author":"M Schulpen","year":"2022","unstructured":"Schulpen M, Goemans BF, Kaspers GJL (2022) Increased survival disparities among children and adolescents & young adults with acute myeloid leukemia: A Dutch population-based study. Int J Cancer 150(7):1101\u20131112. https:\/\/doi.org\/10.1002\/ijc.33878","journal-title":"Int J Cancer"},{"issue":"6","key":"6906_CR40","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41375-018-0314-7","volume":"33","author":"AMJ Reedijk","year":"2019","unstructured":"Reedijk AMJ, Klein K, Coebergh JWW et al (2019) Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality. Leukemia 33(6):1349\u20131359. https:\/\/doi.org\/10.1038\/s41375-018-0314-7","journal-title":"Leukemia"},{"key":"6906_CR41","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1080\/10428190600572673","volume":"47","author":"MJ Greenwood","year":"2006","unstructured":"Greenwood MJ, Seftel MD, Richardson C et al (2006) Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma 47:1245\u20131252. https:\/\/doi.org\/10.1080\/10428190600572673","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"6906_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/pbc.20178","volume":"45","author":"EJ Lowe","year":"2005","unstructured":"Lowe EJ, Pui CH, Hancock ML, Geiger TL, Khan RB, Sandlund JT, Sandlund (2005) Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis. Pediatr Blood Cancer 45(1):10\u201315. https:\/\/doi.org\/10.1002\/pbc.20178","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"6906_CR43","first-page":"149","volume":"31","author":"J Schwartz","year":"2016","unstructured":"Schwartz J, Padmanabhan A, Aqui N et al (2016) Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the seventh special issue. J Clin Apher 31(3):149\u2013162","journal-title":"J Clin Apher"},{"issue":"9","key":"6906_CR44","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.3324\/haematol.2024.285285","volume":"109","author":"B Zeller","year":"2024","unstructured":"Zeller B, Arad-Cohen N, Cheuk D et al (2024) Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 protocol. Haematologica 109(9):2873\u20132883. https:\/\/doi.org\/10.3324\/haematol.2024.285285","journal-title":"Haematologica"},{"issue":"10","key":"6906_CR45","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.3390\/cancers13102336","volume":"13","author":"M Rasche","year":"2021","unstructured":"Rasche M, Zimmermann M, Steidel E et al (2021) Survival following relapse in children with acute myeloid leukemia: a report from AML-BFM and COG. Cancers (Basel) 13(10):2336","journal-title":"Cancers (Basel)"},{"issue":"11","key":"6906_CR46","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1007\/s00277-022-04965-x","volume":"101","author":"R Masetti","year":"2022","unstructured":"Masetti R, Muratore E, Gori D, Prete A, Locatelli F (2022) Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis. Ann Hematol 101(11):2497\u20132506. https:\/\/doi.org\/10.1007\/s00277-022-04965-x","journal-title":"Ann Hematol"},{"issue":"13","key":"6906_CR47","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1182\/blood-2010-01-261800","volume":"116","author":"D Niewerth","year":"2010","unstructured":"Niewerth D, Creutzig U, Bierings MB, Kaspers GJ (2010) A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 116(13):2205\u20132214","journal-title":"Blood"},{"issue":"9","key":"6906_CR48","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3324\/haematol.2014.104182","volume":"99","author":"U Creutzig","year":"2014","unstructured":"Creutzig U, Zimmermann M, Dworzak MN et al (2014) The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001\/01. Haematologica 99(9):1472\u20131478. https:\/\/doi.org\/10.3324\/haematol.2014.104182","journal-title":"Haematologica"},{"issue":"1","key":"6906_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/jcm4010127","volume":"4","author":"JD de Rooij","year":"2015","unstructured":"de Rooij JD, van den Zwaan CM (2015) Pediatric AML: from biology to clinical management. J Clin Med 4(1):127\u2013149. https:\/\/doi.org\/10.3390\/jcm4010127","journal-title":"J Clin Med"},{"issue":"3","key":"6906_CR50","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan N, Weisdorf DJ, Logan BR et al (2015) Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transpl 21(3):454\u2013459. https:\/\/doi.org\/10.1016\/j.bbmt.2014.11.007","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"6906_CR51","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41409-024-02197-3","volume":"59","author":"A Sharma","year":"2024","unstructured":"Sharma A, Galimard JE, Pryce A et al (2024) Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP\/EBMT study. Bone Marrow Transpl 59(4):451\u2013458. https:\/\/doi.org\/10.1038\/s41409-024-02197-3","journal-title":"Bone Marrow Transpl"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06906-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06906-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06906-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:53:53Z","timestamp":1781636033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06906-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6906"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06906-4","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Ethics Committee of Inonu University (approval no. 2024\/5642). Informed consent was obtained from parents of each child.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}